Vetoquinol Overview
- Year Founded
-
1933
- Status
-
Public
- Employees
-
2,486
- Stock Symbol
-
VETO
- Investments
-
12
- Share Price
-
$94.68
- (As of Thursday Closing)
Vetoquinol General Information
Description
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets and livestock (cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families: antibiotics; anti-inflammatories; cardiology and nephrology treatments; and other: anti-parasitics, vaccines, and nutritional products.
Contact Information
Website
www.vetoquinol.comCorporate Office
- 34 rue du chêne Sainte Anne
- Magny-Vernois
- 70204 Lure
- France
Corporate Office
- 34 rue du chêne Sainte Anne
- Magny-Vernois
- 70204 Lure
- France
Vetoquinol Stock Performance
As of 19-Nov-2026, Vetoquinol’s stock price is $94.68. Its current market cap is $1.1B with 11.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $94.68 | $94.98 | $76.43 - $108.59 | $1.1B | 11.6M | 7.96K | $6.35 |
Vetoquinol Financials Summary
As of 30-Jun-2026, Vetoquinol has a trailing 12-month revenue of $615M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 706,218 | 961,599 | 768,060 | 1,248,170 |
| Revenue | 615,157 | 592,977 | 583,463 | 572,711 |
| EBITDA | 136,523 | 124,866 | 115,519 | 118,002 |
| Net Income | 73,294 | 64,702 | 63,503 | 60,120 |
| Total Assets | 879,894 | 896,977 | 774,324 | 765,193 |
| Total Debt | 14,102 | 17,962 | 21,980 | 19,486 |
Vetoquinol Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vetoquinol Comparisons
Industry
Financing
Details
Vetoquinol Competitors (4)
One of Vetoquinol’s 4 competitors is Virbac Australia, a Corporation company based in Sydney, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Virbac Australia | Corporation | Sydney, Australia | ||||
| MSD Animal Health | Corporation | Dublin, Ireland | ||||
| Zoetis | Corporation | Parsippany, NJ | ||||
| Phibro Animal Health | Formerly PE-Backed | Teaneck, NJ |
Vetoquinol Patents
Vetoquinol Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-245953-S | Cardboard packaging box | Active | 12-May-2025 | ||
| EP-4816400-A1 | Anti-canine interleukine-4-receptor alpha (il-4r-alpha) antibodies and the uses thereof | Pending | 30-Nov-2023 | ||
| WO-2025114614-A1 | Anti-canine interleukine-4-receptor alpha (il-4rα) antibodies and the uses thereof | Inactive | 30-Nov-2023 | ||
| EP-4538282-A1 | Synthesis of emodepside | Inactive | 13-Oct-2023 | ||
| EP-4791753-A1 | Synthesis of emodepside | Pending | 13-Oct-2023 | C07K11/02 |
Vetoquinol Signals
Vetoquinol Investments & Acquisitions (12)
Vetoquinol’s most recent deal was a Merger/Acquisition with Vetoquinol Japan. The deal was made on 26-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vetoquinol Japan | 26-Jan-2022 | Merger/Acquisition | Distributors/Wholesale | ||
| Elanco (Drontal and Profender European Economic Area and UK Rights) | 12-Feb-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Clarion Biociências | 16-Apr-2019 | Merger/Acquisition | Other Commercial Products | ||
| VetIMPRESS | 06-Sep-2018 | Merger/Acquisition | Business/Productivity Software | ||
| Plant Advanced Technologies PAT | 13-Nov-2017 | PIPE | Other Commercial Services |
Vetoquinol ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
27.24 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Vetoquinol Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vetoquinol Japan | Tokyo, Japan | 2015 | |
| VetIMPRESS | Moneymore, United Kingdom | 2010 | |
| Vetoquinol International | Magny-Vernois, France | 2007 | |
| Vetoquinol Scandinavia | Aastorp, Sweden | 2004 |
Vetoquinol FAQs
-
When was Vetoquinol founded?
Vetoquinol was founded in 1933.
-
Where is Vetoquinol headquartered?
Vetoquinol is headquartered in Lure, France.
-
What is the size of Vetoquinol?
Vetoquinol has 2,486 total employees.
-
What industry is Vetoquinol in?
Vetoquinol’s primary industry is Other Agriculture.
-
Is Vetoquinol a private or public company?
Vetoquinol is a Public company.
-
What is Vetoquinol’s stock symbol?
The ticker symbol for Vetoquinol is VETO.
-
What is the current stock price of Vetoquinol?
As of 19-Nov-2026 the stock price of Vetoquinol is $94.68.
-
What is the current market cap of Vetoquinol?
The current market capitalization of Vetoquinol is $1.1B.
-
What is Vetoquinol’s current revenue?
The trailing twelve month revenue for Vetoquinol is $615M.
-
Who are Vetoquinol’s competitors?
Virbac Australia, MSD Animal Health, Zoetis, and Phibro Animal Health are competitors of Vetoquinol.
-
What is Vetoquinol’s annual earnings per share (EPS)?
Vetoquinol’s EPS for 12 months was $6.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process